Contribution of oncoproteomics to cancer biomarker discovery

Molecular Cancer

Volumn 6, Issue , 2007, Pages

  Cho, William C S ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CYTOKERATIN 19 FRAGMENT; DECARBOXYPROTHROMBIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLIC ACID; GEFITINIB; IMATINIB; IRINOTECAN; NUCLEAR MATRIX PROTEIN 22; PROSTATE SPECIFIC ANTIGEN; PROTEASOME INHIBITOR; TRASTUZUMAB; TUMOR MARKER; PROTEOME;

B CELL LYMPHOMA; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SCREENING; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COST CONTROL; DNA MICROARRAY; DNA REPAIR; DRUG TARGETING; EARLY DIAGNOSIS; ECHOGRAPHY; ESOPHAGUS CANCER; FUNCTIONAL PROTEOMICS; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GLIOMA; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; KIDNEY CANCER; LEUKEMIA; LIVER CELL CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MONOTHERAPY; NASOPHARYNX CARCINOMA; OVARY CANCER; PANCREAS CANCER; PATHOPHYSIOLOGY; PROGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TRANSVAGINAL ECHOGRAPHY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UROGENITAL TRACT TUMOR; METABOLISM; NEOPLASM; PROTEOMICS;

HUMANS; NEOPLASMS; PROGNOSIS; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 34247282875     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-6-25     Document Type: Review

References (95)

1. Cho WC Proteomics-leading biological science in the 21st century Sci J 2004 56 14-17
2. Cho WC Research progress in SELDI-TOF MS and its clinical applications Sheng Wu Gong Cheng Xue Bao 2006 22 871-876 17168305
3. Kurebayashi J Biomarkers in breast cancer Gan To Kagaku Ryoho 2004 31 1021-1026 15272579
4. Yim EK Park JS Role of proteomics in translational research in cervical cancer Expert Rev Proteomics 2006 3 21-36 10.1586/14789450.3.1.21 16445348
5. Lopez JB Recent developments in the first detection of hepatocellular carcinoma Clin Biochem Rev 2005 26 65-79 1240033 16450014
6. Vukotic V Cerovic S Kozomara M Lazic M The predictive value of PSA in diagnosis of prostate cancer in non screened population Acta Chir Iugosl 2005 52 81-87 16673602
7. Goufman EI Moshkovskii SA Tikhonova OV Lokhov PG Zgoda VG Serebryakova MV Toropygin IY Vlasova MA Safarova MR Makarov OV Archakov AI Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions Biochemistry (Mosc) 2006 71 354-360 10.1134/S000629790604002X 16615854
8. Celis JE Gromov P Proteomics in translational cancer research: Toward an integrated approach Cancer Cell 2003 3 9-15 10.1016/ S1535-6108(02)00242-8 12559171
9. Sheng KH Yao YC Chuang SS Wu H Wu TF Search for the tumor-related proteins of transition cell carcinoma in Taiwan by proteomic analysis Proteomics 2006 6 1058-1065 10.1002/pmic.200402015 16400682
10. Pawlik TM Hawke DH Liu Y Krishnamurthy S Fritsche H Hunt KK Kuerer HM Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein BMC Cancer 2006 6 68 1431555 16542425 10.1186/1471-2407-6-68
11. Madoz-Gurpide J Lopez-Serra P Martinez-Torrecuadrada JL Sanchez L Lombardia L Casal JI Proteomics-based validation of genomic data: applications in colorectal cancer diagnosis Mol Cell Proteomics 2006 5 1471-1483 10.1074/mcp.M600048-MCP200 16733264
12. Xing X Lai M Gartner W Xu E Huang Q Li H Chen G Identification of differentially expressed proteins in colorectal cancer by proteomics: down-regulation of secretagogin Proteomics 2006 6 2916-2923 10.1002/ pmic.200401355 16586428
13. Nomura F Clinical proteomics in laboratory medicine Rinsho Byori 2006 54 413-420 16722462
14. Nishimori T Tomonaga T Matsushita K Kodera Y Maeda T Nomura F Matsubara H Shimada H Ochiai T Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin Proteomics 2006 6 1011-1018 10.1002/pmic.200500262 16400690
15. Kang HJ Koh KH Yang E Oh-Ishi M You KT Kim HJ Paik YK Kim H Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations Proteomics 2006 6 1151-1157 10.1002/ pmic.200500372 16402362
16. Schwartz SA Weil RJ Thompson RC Shyr Y Moore JH Toms SA Johnson MD Caprioli RM Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry Cancer Res 2005 65 7674-7681 16140934
17. Kawakami T Hoshida Y Kanai F Tanaka Y Tateishi K Ikenoue T Obi S Sato S Teratani T Shiina S Kawabe T Suzuki T Hatano N Taniguchi H Omata M Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment Proteomics 2006 5 4287-4295 10.1002/ pmic.200401287
18. Lee IN Chen CH Sheu JC Lee HS Huang GT Yu CY Lu FJ Chow LP Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry J Proteome Res 2005 4 2062-2069 10.1021/pr0502018 16335951
19. Lee IN Chen CH Sheu JC Lee HS Huang GT Chen DS Yu CY Wen CL Lu FJ Chow LP Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach Proteomics 2006 6 2865-2873 10.1002/pmic.200500488 16586433
20. Melle C Ernst G Scheibner O Kaufmann R Schimmel B Bleul A Settmacher U Hommann M Claussen U Eggeling FV Identification of specific protein markers in microdissected hepatocellular carcinoma J Proteome Res 2007 6 306-315 10.1021/pr060439b 17203974
21. Christopherson RI Stoner K Barber N Belov L Woolfson A Scott M Bendall L Mulligan SP Classification of AML using a monoclonal antibody microarray Methods Mol Med 2006 125 241-251 16502589
22. Maciel CM Junqueira M Paschoal ME Kawamura MT Duarte RL Carvalho Mda G Domont GB Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients J Exp Ther Oncol 2005 5 31-38 16416599
23. Fan G Molstad M Braziel RM Standley M Huang J Rodgers W Nagalla S Proteomic profiling of mature CD10+ B-cell lymphomas Am J Clin Pathol 2005 124 920-929 10.1309/UEDX-PHAA-P740-B61D 16416742
24. Doustjalali SR Yusof R Govindasamy GK Bustam AZ Pillay B Hashim OH Patients with nasopharyngeal carcinoma demonstrate enhanced serum and tissue ceruloplasmin expression J Med Invest 2006 53 20-28 10.2152/ jmi.53.20 16537992
25. Ahmed N Oliva KT Barker G Hoffmann P Reeve S Smith IA Quinn MA Rice GE Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer Proteomics 2005 5 4625-4636 10.1002/pmic.200401321 16220531
26. Bloomston M Zhou JX Rosemurgy AS Frankel W Muro-Cacho CA Yeatman TJ Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples Cancer Res 2006 66 2592-2599 10.1158/0008-5472.CAN-05-3659 16510577
27. Crnogorac-Jurcevic T Gangeswaran R Bhakta V Capurso G Lattimore S Akada M Sunamura M Prime W Campbell F Brentnall TA Costello E Neoptolemos J Lemoine NR Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma Gastroenterology 2005 129 1454-1463 10.1053/ j.gastro.2005.08.012 16285947
28. Ornstein DK Tyson DR Proteomics for the identification of new prostate cancer biomarkers Urol Oncol 2006 24 231-236 16678055
29. Junker K von Eggeling F Muller J Steiner T Schubert J Identification of biomarkers and therapeutic targets for renal cell cancer using ProteinChip technology Urologe A 2006 45 305-315 10.1007/ s00120-006-1001-2 16491405
30. Theodorescu D Wittke S Ross MM Walden M Conaway M Just I Mischak H Frierson HF Discovery and validation of new protein biomarkers for urothelial cancer: A prospective analysis Lancet Oncol 2006 7 230-240 10.1016/S1470-2045(06)70584-8 16510332
31. Nedelkov D Kiernan UA Niederkofler EE Tubbs KA Nelson RW Population proteomics: The concept, attributes, and potential for cancer biomarker research Mol Cell Proteomics 2006 5 1811-1818 10.1074/mcp.R600006-MCP200 16735302
32. Gires O Mack B Rauch J Matthias C CK8 correlates with malignancy in leukoplakia and carcinomas of the head and neck Biochem Biophys Res Commun 2006 343 252-259 10.1016/j.bbrc.2006.02.139 16540085
33. Hornberg JJ Bruggeman FJ Westerhoff HV Lankelma J Cancer: A Systems Biology disease Biosystems 2006 83 81-90 10.1016/ j.biosystems.2005.05.014 16426740
34. Ajani J Allgood V Molecular mechanisms in cancer: What should clinicians know? Semin Oncol 2005 32 2-4 10.1053/j.seminoncol.2005.07.016 16360003
35. Petricoin EF Liotta LA Proteomic approaches in cancer risk and response assessment Trends Mol Med 2004 10 59-64 10.1016/j.molmed.2003.12.006 15102358
36. Le Guezennec X Brinkman AB Vermeulen M Denissov SG Gazziola C Lohrum ME Stunnenberg HG Targeted discovery tools: Proteomics and chromatin immunoprecipitation-on-chip BJU Int 2005 96 Suppl 2 16-22 10.1111/ j.1464-410X.2005.05942.x 16359434
37. Bi X Lin Q Foo TW You T Shen HM Ong CN Cheah PY Eu KW Hew CL Proteomics analysis of colorectal cancer reveals alterations in metabolic pathways - mechanism of tumorigenesis Mol Cell Proteomics 2006 5 1119-1130 10.1074/mcp.M500432-MCP200 16554294
38. Mazzanti R Solazzo M Fantappie O Elfering S Pantaleo P Bechi P Cianchi F Ettl A Giulivi C Differential expression proteomics of human colon cancer Am J Physiol Gastrointest Liver Physiol 2006 290 G1329-G1338 10.1152/ajpgi.00563.2005 16439467
39. Breikers G van Breda SG Bouwman FG van Herwijnen MH Renes J Mariman EC Kleinjans JC van Delft JH Potential protein markers for nutritional health effects on colorectal cancer in the mouse as revealed by proteomics analysis Proteomics 2006 6 2844-2852 10.1002/pmic.200500067 16596712
40. Yan G Li L Tao Y Liu S Liu Y Luo W Wu Y Tang M Dong Z Cao Y Identification of novel phosphoproteins in signaling pathways triggered by latent membrane protein 1 using functional proteomics technology Proteomics 2006 6 1810-1821 10.1002/pmic.200500156 16470631
41. Perroud B Lee J Valkova N Dhirapong A Lin PY Fiehn O Kultz D Weiss RH Pathway analysis of kidney cancer using proteomics and metabolic profiling Mol Cancer 2006 5 64 1665458 17123452 10.1186/1476-4598-5-64
42. Overall CM Dean RA Degradomics: Systems biology of the protease web. Pleiotropic roles of MMPs in cancer Cancer Metastasis Rev 2006 25 69-75 10.1007/s10555-006-7890-0 16680573
43. Wang Y Hanley R Klemke RL Computational methods for comparison of large genomic and proteomic datasets reveal protein markers of metastatic cancer J Proteome Res 2006 5 907-915 10.1021/pr050390u 16602698
44. Jessani N Liu Y Humphrey M Cravatt BF Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness Proc Natl Acad Sci USA 2002 99 10335-10340 124915 12149457 10.1073/ pnas.162187599
45. Cobleigh MA Vogel CL Tripathy D Robert NJ Scholl S Fehrenbacher L Wolter JM Paton V Shak S Lieberman G Slamon DJ Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 1999 17 2639-2648 10561337
46. Slamon DJ Leyland-Jones B Shak S Fuchs H Paton V Bajamonde A Fleming T Eiermann W Wolter J Pegram M Baselga J Norton L Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 2001 344 783-792 10.1056/ NEJM200103153441101 11248153
47. Esteva FJ Valero V Booser D Guerra LT Murray JL Pusztai L Cristofanilli M Arun B Esmaeli B Fritsche HA Sneige N Smith TL Hortobagyi GN Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer J Clin Oncol 2002 20 1800-1808 10.1200/JCO.2002.07.058 11919237
48. Vogel CL Cobleigh MA Tripathy D Gutheil JC Harris LN Fehrenbacher L Slamon DJ Murphy M Novotny WF Burchmore M Shak S Stewart SJ Press M Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 2002 20 719-726 10.1200/JCO.20.3.719 11821453
49. Souchelnytskyi S Proteomics of TGF-beta signaling and its impact on breast cancer Expert Rev Proteomics 2005 2 925-935 10.1586/ 14789450.2.6.925 16307521
50. Van Custem E Labianca R Cognetti E Targeted therapies for patients with advanced colorectal cancer: Focus on cetuximab Targ Oncol 2006 1 2-12 10.1007/s11523-005-0001-2
51. Nissom PM Lo SL Lo JC Ong PF Lim JW Ou K Liang RC Seow TK Chung MC Hcc-2, a novel mammalian ER thioredoxin that is differentially expressed in hepatocellular carcinoma FEBS Lett 2006 580 2216-2226 10.1016/ j.febslet.2006.03.029 16574106
52. Fong L Small EJ Immunotherapy for prostate cancer Curr Urol Rep 2006 7 239-246 16630528
53. Jain KK Role of pharmacoproteomics in the development of personalized medicine Pharmacogenomics 2004 5 331-336 10.1517/phgs.5.3.331.29830 15102547
54. Verrills NM Kavallaris MaL Drug resistance mechanisms in cancer cells: A proteomics perspective Curr Opin Mol Ther 2003 5 258-265 12870435
55. Grossman HB Soloway M Messing E Katz G Stein B Kassabian V Shen Y Surveillance for recurrent bladder cancer using a point-of-care proteomic assay JAMA 2006 295 299-305 10.1001/jama.295.3.299 16418465
56. Neubauer H Clare SE Kurek R Fehm T Wallwiener D Sotlar K Nordheim A Wozny W Schwall GP Poznanovic S Sastri C Hunzinger C Stegmann W Schrattenholz A Cahill MA Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detection Electrophoresis 2006 27 1840-1852 10.1002/ elps.200500739 16645950
57. Ricolleau G Charbonnel C Lode L Loussouarn D Joalland MP Bogumil R Jourdain S Minvielle S Campone M Deporte-Fety R Campion L Jezequel P Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors Proteomics 2006 6 1963-1975 10.1002/pmic.200500283 16470659
58. Liu Y Liu H Han B Zhang JT Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis Cancer Res 2006 66 3248-3255 10.1158/ 0008-5472.CAN-05-3801 16540677
59. Luk JM Lam CT Siu AF Lam BY Ng IO Hu MY Che CM Fan ST Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values Proteomics 2006 6 1049-1057 10.1002/ pmic.200500306 16400691
60. Ferrari G Pastorelli R Buchi F Spinelli E Gozzini A Bosi A Santini V Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance J Proteome Res 2007 6 367-375 10.1021/pr0603708 17203980
61. Loni L De Braud F Zinzani PL Danesi R Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma Leuk Lymphoma 2003 44 Suppl 3 S115-122 10.1080/10428190310001623676 15202534
62. Voss T Ahorn H Haberl P Dohner H Wilgenbus K Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia Int J Cancer 2001 91 180-186 10.1002/ 1097-0215(200002)9999:9999<::AID-IJC1037>3.0.CO;2-J 11146442
63. Cho WC Yip TT Yip C Yip V Thulasiraman V Ngan RK Yip TT Lau WH Au JS Law SC Cheng WW Ma VW Lim CK Identification of serum amyloid A protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling Clin Cancer Res 2004 10 43-52 10.1158/ 1078-0432.CCR-0413-3 14734450
64. Cho WC Nasopharyngeal carcinoma: Molecular biomarker discovery and progress Mol Cancer 2007 6 1 1774581 17199893 10.1186/1476-4598-6-1
65. Cho WC Yip TT Ngan RK Yip TT Podust VN Yip C Yiu HH Yip V Cheng WW Ma VW Law SC Proteinchip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma Clin Chem 2007 53 241-250 10.1373/clinchem.2005.065805 17200135
66. Li Z Zhao X Yang J Wei Y Proteomics profile changes in cisplatin-treated human ovarian cancer cell strain Sci China C Life Sci 2005 48 648-657 10.1360/062004-84 16483145
67. Bast RC Jr Badgwell D Lu Z Marquez R Rosen D Liu J Baggerly KA Atkinson EN Skates S Zhang Z Lokshin A Menon U Jacobs I Lu K New tumor markers: CA125 and beyond Int J Gynecol Cancer 2005 15 Suppl 3 274-281 10.1111/ j.1525-1438.2005.00441.x 16343244
68. Shi Y Hill J Xiang R Horvath C Wilkins JA Multistep mass tagging coupled with 2D LC-MS-an approach to increasing the number of identified proteins J Biomol Tech 2005 16 190-196 16461942
69. Chen EI Hewel J Felding-Habermann B Yates JR 3rd Large scale protein profiling by combination of protein fractionation and multidimensional protein identification technology (MudPIT) Mol Cell Proteomics 2006 5 53-56 10.1074/mcp.T500013-MCP200 16272560
70. Crockett DK Lin Z Vaughn CP Lim MS Elenitoba-Johnson KS Identification of proteins from formalin-fixed paraffin-embedded cells by LC-MS/MS Lab Invest 2005 85 1405-1415 10.1038/labinvest.3700343 16155593
71. Rajapakse JC Duan KB Yeo WK Proteomic cancer classification with mass spectrometry data Am J Pharmacogenomics 2005 5 281-292 10.2165/ 00129785-200505050-00001 16196498
72. Drake SK Bowen RA Remaley AT Hortin GL Potential interferences from blood collection tubes in mass spectrometric analyses of serum polypeptides Clin Chem 2004 50 2398-2401 10.1373/clinchem.2004.040303 15563493
73. White CN Chan DW Zhang Z Bioinformatics strategies for proteomic profiling Clin Biochem 2004 37 636-641 10.1016/j.clinbiochem.2004.05.004 15234244
74. Colantonio DA Chan DW The clinical application of proteomics Clin Chim Acta 2005 357 151-158 10.1016/j.cccn.2005.03.020 15896729
75. Wang H Qian WJ Mottaz HM Clauss TR Anderson DJ Moore RJ Camp DG 2nd Khan AH Sforza DM Pallavicini M Smith DJ Smith RD Development and evaluation of a micro- and nanoscale proteomic sample preparation method J Proteome Res 2005 4 2397-2403 1781925 16335993 10.1021/pr050160f
76. Kolch W Mischak H Pitt AR The molecular make-up of a tumor: Proteomics in cancer research Clin Sci (Lond) 2005 108 369-383 15831087
77. Cottingham K Speeding up biomarker discovery J Proteome Res 2006 5 1047-1048
78. Nishio K Sugimoto Y Kaashara K Sakuma T Terui Y Ueno K Yumoto H Yamauchi K Yamamura K Mimura H Sano Y Yabashi M Tamasaku K Nishio K Nishino Y Endo K Hatake K Mori Y Ishizaka Y Ishikawa T Element array by scanning X-ray fluorescence microscopy after cis-diamminedichloro-platinum(II) treatment Int J Cancer 1992 50 438-442 10.1002/ijc.2910500319 1310490
79. Banerjee A Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells Biochem Biophys Res Commun 2002 293 598-601 10.1016/ S0006-291X(02)00269-3 12054644
80. Christian Beck H Nielsen EC Matthiesen R Jensen LH Sehested M Finn P Grauslund M Hansen AM Jensen ON Quantitative proteomic analysis of post-translational modifications of human histones Mol Cell Proteomics 2006 5 1314-1325 10.1074/mcp.M600007-MCP200 16627869
81. Jain KK Role of oncoproteomics in the personalized management of cancer Expert Rev Proteomics 2004 1 49-55 10.1586/14789450.1.1.49 15966798
82. Jain KK Personalised medicine for cancer: From drug development into clinical practice Expert Opin Pharmacother 2005 6 1463-1476 10.1517/ 14656566.6.9.1463 16086635
83. Jain KK Recent advances in oncoproteomics Curr Opin Mol Ther 2002 4 203-209 12139304
84. Cho WC Cheng CH Oncoproteomics technologies - current trends and future perspectives Expert Rev Proteomics 2007 10.1016/j.ddtec.2004.06.002
85. Cho WC Nanomedicine Sci J 2005 57 8-10
86. Gulmann C Sheehan KM Kay EW Liotta LA Petricoin EF 3rd Array-based proteomics: Mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer J Pathol 2006 208 595-606 10.1002/ path.1958 16518808
87. Mueller J von Eggeling F Driesch D Schubert J Melle C Junker K ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients Eur Urol 2005 47 885-894 10.1016/ j.eururo.2005.02.016 15925088
88. Li J Zhang Z Rosenzweig J Wang YY Chan DW Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer Clin Chem 2002 48 1296-304 12142387
89. Chen YD Zheng S Yu JK Hu X Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population Clin Cancer Res 2004 10 8380-8385 10.1158/1078-0432.CCR-1162-03 15623616
90. Poon TC Sung JJ Chow SM Ng EK Yu AC Chu ES Hui AM Leung WK Diagnosis of gastric cancer by serum proteomic fingerprinting Gastroenterology 2006 130 1858-1864 10.1053/j.gastro.2006.02.011 16697748
91. Ward DG Cheng Y N'Kontchou G Thar TT Barget N Wei W Billingham LJ Martin A Beaugrand M Johnson PJ Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis Br J Cancer 2006 94 287-292 10.1038/sj.bjc.6602923 16404431
92. Yang SY Xiao XY Zhang WG Zhang LJ Zhang W Zhou B Chen G He DC Application of serum SELDI proteomic patterns in diagnosis of lung cancer BMC Cancer 2005 5 83 1183195 16029516 10.1186/1471-2407-5-83
93. Zhang Z Bast RC Jr Yu Y Li J Sokoll LJ Rai AJ Rosenzweig JM Cameron B Wang YY Meng XY Berchuck A Van Haaften-Day C Hacker NF de Bruijn HW van der Zee AG Jacobs IJ Fung ET Chan DW Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer Cancer Res 2004 64 5882-5890 10.1158/0008-5472.CAN-04-0746 15313933
94. Koopmann J Zhang Z White N Rosenzweig J Fedarko N Jagannath S Canto MI Yeo CJ Chan DW Goggins M Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry Clin Cancer Res 2004 10 860-868 10.1158/1078-0432.CCR-1167-3 14871961
95. Adam BL Qu Y Davis JW Ward MD Clements MA Cazares LH Semmes OJ Schellhammer PF Yasui Y Feng Z Wright GL Jr Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men Cancer Res 2002 62 3609-3614 12097261